Investor Relations

Bringing Science to Society™

Company Overview

In the first quarter of 2022, we announced our transformation from Recro to Societal™ CDMO. With this change, we are committed to helping our partners expedite the delivery of life-changing pharmaceuticals to patients.

Societal CDMO (NASDAQ: SCTL) is a bi-coastal contract development and manufacturing organization (CDMO) with capabilities spanning pre-Investigational New Drug (IND) development to commercial manufacturing and packaging for a wide range of therapeutic dosage forms with a primary focus in the area of small molecules. With an expertise in solving complex manufacturing problems, Societal CDMO is a leading CDMO providing therapeutic development, end-to-end regulatory support, clinical and commercial manufacturing, aseptic fill/finish, lyophilization, packaging, and logistics services to the global pharmaceutical market.

In addition to our experience in handling DEA controlled substances and developing and manufacturing modified-release dosage forms, Societal CDMO has the expertise to deliver on our clients’ pharmaceutical development and manufacturing projects, regardless of complexity level. We do all of this in our best-in-class facilities, totaling 145,000 square feet, in Gainesville, Georgia, and San Diego, California.

Latest Financial Results

Q1 2021

Quarter Ended Mar 31, 2021

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2021

Stock Snapshot

IR Contacts

Company

Societal CDMO
1 E. Uwchlan Ave
Suite 112
Exton, PA 19341
T: 770-531-8365
investorrelations@societalcdmo.com

Investor Relations

Vida Strategic Partners
Stephanie Diaz
T: 415-675-7401
sdiaz@vidasp.com

Market Data copyright © 2022 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.